Company Focus
Icon
Latest Icon News
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Latest News & Features of interest to Icon
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK pharma major GSK that targets interleukin-5 (IL-5). 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Biotechnology
US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy 2 January 2025
Biotechnology
China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. 2 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Biotechnology
California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload antibody-drug conjugate (ADC) program with China’s Jiangsu Hengrui Pharmaceuticals. 2 January 2025
Biotechnology
Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an all-share acquisition by HOOKIPA of London-listed Poolbeg to create a strong clinical-stage biopharmaceutical company. 2 January 2025
Latest In Brief for Icon
Biotechnology
TJ Bio has reportedly submitted a biologics license application (BLA) to China’s Center for Drug Evaluation for GX-H9 (eftansomatropin alfa), a second-generation therapy for pediatric growth hormone deficiency. 31 December 2024
Latest Relevant Ones To Watch News
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
2 January 2025
27 December 2024
19 December 2024
17 December 2024
16 December 2024
16 December 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze